Archive | May, 2011

Energy,Technology and Healthcare Sectors Pace Gains Today

Despite the continuing gloomy backdrop of a Greece default, U.S, debt ceiling and weak housing data, several market  sectors rallied today. The NASDAQ was the leader up 1.37% and the S&P was up 1.06%. Energy was the sector leader up 1.39% helped by higher crude (WTI Crude $102.70) and nat gas prices ($4.69).A stronger Euro […]

Continue Reading 0

Rayno Life Science Portfolio: AMRI, GILD, NKTR, OPTR all up

The life science market continued to show resilience today with a few big movers and a bidding up of  large cap drugs such as Johnson and Johnson (JNJ $67.15), Novartis (NVS $64.24), Pfizer(PFE $21.21) and Sanofi-Aventis (SNY $39.42). Foreign drug companies fared better up ~1.5% probably because of strength of the Euro. The Rayno Life […]

Continue Reading 0

Stocks to Watch: ASCO -continued-INCY, ONXX, SUPG

This is a continuation of pre-ASCO coverage, reviewing companies that will have significant clinical presentations on cancer products in their pipeline. Incyte Corporation (INCY $17.82) up 1.94%. is focused on small molecule drugs for hematological and oncology applications and for chronic autoimmune and inflammatory diseases.In oncology the Company has four indications for its JAK inhibitor […]

Continue Reading 0

New: Guide to Biotech Investing and ETF’s

Our recent article on biotech investing and ETF’s in general are posted on Investor Uprising. Note to get the article on the right side of the page you need to register at no charge for Investor Uprising. Investor Uprising – IU Education – Guide to Biotech Investing

Continue Reading 0

Stocks to Watch: ASCO Presentations for ARIA,DNDN,ECYT and EXEL

Here is a brief review of stocks to watch with potential ASCO impact although it is likely that prices already reflect the scientific news: Ariad Pharmaceuticals Inc. (ARIA $8.43) up 0.36% will present Phase III data on ponatinab, its investigational pan-BCR-ABL and ridaforolimus an mTOR inhibitor both with multiple indications.An investor presentation will be held […]

Continue Reading 0

Medical Science News Ramping Up for ASCO

A bull market in life science stocks has revved up news for the upcoming ASCO Meeting on June 3 in Chicago. We will provide limited coverage of stocks to watch and scientific articles of interest. However it is clear that many PR shops and newsletters are busy preparing investors with lists of clinical stage cancer […]

Continue Reading 0

Personalized Healthcare Gets a Boost from Nestle/Prometheus Deal

The Life Science market consolidation trend continued  today as Nestle SA acquires privately held Prometheus Laboratories, Inc. of San Diego,CA for about $567M according to a Bloomberg story although the price was not disclosed. Other stories put the price closer to $1B.Prometheus was forecasted to have revenues of $250M next year (they might be much higher) […]

Continue Reading 0

The Red Screen is the Winner Today But Cubist (CBST) Is Up On Buyout Rumors

It was a nasty day from the beginning but losses abated as the day wore on. The NASDAQ was off 1.68%, the Dow down 1.05% and the S&P down 1.15% to 1317. The S&P held trend lines in the 1312-1315 range. Biotech ETF’s were also losers IBB off 1.5%, FBT off 1.6% and XBI off […]

Continue Reading 0

ASCO June 3-7 Chicago: Rally Today

The pre-ASCO hype has already begun but many biopharma stocks have already run up 15%+ YTD. So it is time to be cautious as there may be an “ASCO Effect”- a sell on the news effect. Despite a weak tape in the major indices the life science sector has a lot of green. Today there […]

Continue Reading 0

Rayno Life Science Portfolio Winners Today: ABAX,CBST,CSII,NEOG

M&A Premium Rocks On In a flat life science market eclipsed by the LinkedIn (LNKD) IPO and its day trading frenzy, many life science stocks in the Rayno Life Science Portfolio logged decent gains. As reported earlier today GenProbe(GPRO) sold off down 4.37% but it was up 8% yesterday. After ThermoFisher bought allergy Dx leader […]

Continue Reading 0